Catechins: Therapeutic Perspectives in COVID-19-Associated Acute Kidney Injury.
Lúcio Ricardo Leite DinizHatem A ElshabrawyMarilia Trindade de Santana SouzaAllana Brunna Sucupira DuarteSabarno DattaDamião Pergentino de SousaPublished in: Molecules (Basel, Switzerland) (2021)
Data obtained from several intensive care units around the world have provided substantial evidence of the strong association between impairment of the renal function and in-hospital deaths of critically ill COVID-19 patients, especially those with comorbidities and requiring renal replacement therapy (RRT). Acute kidney injury (AKI) is a common renal disorder of various etiologies characterized by a sudden and sustained decrease of renal function. Studies have shown that 5-46% of COVID-19 patients develop AKI during hospital stay, and the mortality of those patients may reach up to 100% depending on various factors, such as organ failures and RRT requirement. Catechins are natural products that have multiple pharmacological activities, including anti-coronavirus and reno-protective activities against kidney injury induced by nephrotoxic agents, obstructive nephropathies and AKI accompanying metabolic and cardiovascular disorders. Therefore, in this review, we discuss the anti-SARS-CoV-2 and reno-protective effects of catechins from a mechanistic perspective. We believe that catechins may serve as promising therapeutics in COVID-19-associated AKI due to their well-recognized anti-SARS-CoV-2, and antioxidant and anti-inflammatory properties that mediate their reno-protective activities.
Keyphrases
- sars cov
- acute kidney injury
- cardiac surgery
- respiratory syndrome coronavirus
- anti inflammatory
- end stage renal disease
- intensive care unit
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute care
- prognostic factors
- small molecule
- oxidative stress
- type diabetes
- coronavirus disease
- cardiovascular events
- cardiovascular disease
- risk factors
- mechanical ventilation